Ipsen initiates a new share buy-back program PARIS, FRANCE, 18 MAY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it has appointed an investment services provider to purchase an aggregate number of up to 350,000 Ipsen S.A. shares, representing approximately 0.42% of the share capital, over a maximum period of six months. The shares purchased under this agreement will be allocated mainly to cover Ipsen’s free employee share-allocation plan and its new employee share-ownership plan. This program is made pursuant to the authorization granted by the Company’s Annual General Meeting, held on 13 May 2026. About IpsenWe are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal...

ATLANTA, May 18, 2026 (GLOBE NEWSWIRE) — Bitcoin Depot (NASDAQ: BTM), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, today announced that it has initiated a voluntary Chapter 11 process in the U.S. Bankruptcy Court for the Southern District of Texas to effect an orderly wind-down of the Company’s operations and facilitate a sale of its assets. “Over time, the Company has continued to strengthen its protocols and procedures to combat fraud and protect the customers who use its BTMs, including enhanced identity verification, customer fraud warnings, and its more recent adoption of lower transaction limits for its customers,” said Alex Holmes, CEO of Bitcoin Depot. “Nevertheless, the regulatory environment for BTM operators has shifted significantly: states have imposed increasingly stringent compliance obligations,...

SAN FRANCISCO, May 17, 2026 (GLOBE NEWSWIRE) — Life360, Inc. (NASDAQ: LIF; ASX: 360), the provider of the market-leading family safety and connection mobile application, today announced that its Board of Directors has authorized management’s deployment of a multi-year share repurchase program of up to $225 million (the “Program”). The objective of the Program is designed to return value to our shareholders by minimizing dilution from stock-based instruments. The Program represents a productive deployment of the Company’s capital, supported by a strong balance sheet and twelve consecutive quarters of positive operating cash flow. “We remain focused on investing in the Life360 platform as we grow our global member base and deepen the value we deliver to families,” said Life360 Chief Executive Officer Lauren Antonoff. “This targeted...

CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich’s ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. A live webcast of the presentation will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC®...

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weekssNDA filed in US, China and Japan; decisions expected H2 2026Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026. Results show that patients treated with Pluvicto experienced a higher frequency and depth of PSA response when combined with SoC (androgen receptor pathway...

Eimskip and Faroe Ship have received a notice from the Seafarers’ Union of Iceland (SÍ) announcing an indefinite strike by bosuns and able seamen on the Company’s own vessels Brúarfoss, Dettifoss, and Selfoss, effective from 12:00 PM on Monday, May 25, if an agreement hasn´t been reached before that time. The agreement with SÍ members on the Company’s own vessels expired at the end of last year. During the validity period, the agreement has changed in line with general labor market wage increases under the so-called stability agreement, as well as additional increases agreed for these roles. SÍ had previously announced a temporary strike on the Company’s own vessels scheduled for April 12.-15. which was withdrawn on April 8. A temporary strike by harbor employees, originally announced for April 13, was postponed until the period of May...

Data presented by Johnson & Johnson at the 2026 European Society for Radiotherapy and Oncology (ESTRO) Annual Meeting PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) —  NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of Part 1 data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer (“NSCLC”), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting (ESTRO 2026). PRESENTATION #116: Radiographic Response...

MIAMI, FL, May 17, 2026 (GLOBE NEWSWIRE) — NextNRG, Inc. (NASDAQ: NXXT), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced it will host a conference call on Monday, May 18, 2026 at 9:00 a.m. Eastern Time to discuss its first quarter 2026 financial results and provide a corporate update. This release corrects a previously issued announcement to reflect updated conference call details. Conference Call Details •  Date: Monday, May 18, 2026 •  Time: 9:00 a.m. Eastern Time •  Participant Dial-In (U.S. Toll-Free): 877-407-9219 / +1 412-652-1274 •  Participant Dial-In (International): +1 412-652-1274 (additional international numbers available at www.incommconferencing.com/international-dial-in) •  Participant Dial-In (Canada Toll-Free): 877-407-9219 / +1 412-652-1274 Webcast...